Johnson & Johnson (NYSE:JNJ) Shares Sold by Raelipskie Partnership

Raelipskie Partnership cut its holdings in Johnson & Johnson (NYSE:JNJ) by 1.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,428 shares of the company’s stock after selling 262 shares during the period. Johnson & Johnson comprises about 1.1% of Raelipskie Partnership’s holdings, making the stock its 21st largest position. Raelipskie Partnership’s holdings in Johnson & Johnson were worth $2,176,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of JNJ. Innealta Capital LLC purchased a new position in Johnson & Johnson in the second quarter valued at approximately $27,000. Highline Wealth Partners LLC acquired a new stake in Johnson & Johnson during the 3rd quarter worth $31,000. RPg Family Wealth Advisory LLC purchased a new stake in Johnson & Johnson in the third quarter valued at $35,000. Mowery & Schoenfeld Wealth Management LLC boosted its stake in Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after acquiring an additional 91 shares in the last quarter. Finally, Activest Wealth Management acquired a new stake in shares of Johnson & Johnson during the third quarter worth about $40,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on JNJ shares. Wolfe Research started coverage on Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Citigroup upped their target price on shares of Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Finally, Guggenheim raised their price target on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Seven analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $175.67.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $149.31 on Monday. The stock has a 50 day simple moving average of $158.09 and a 200-day simple moving average of $156.40. The company has a market cap of $359.48 billion, a price-to-earnings ratio of 21.61, a price-to-earnings-growth ratio of 2.65 and a beta of 0.51. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. During the same period in the prior year, the company posted $2.66 EPS. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. On average, equities analysts forecast that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.32%. Johnson & Johnson’s payout ratio is 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.